**Ei24, a Novel E2F Target Gene, Affects p53-independent Cell Death upon Ultraviolet C Irradiation**

Received for publication, April 15, 2013, and in revised form, September 6, 2013. Published, JBC Papers in Press, September 6, 2013, DOI 10.1074/jbc.M113.477570

Young Hoon Sung‡1,2, Young Jin‡, Yunhwa Kang‡, Sushil Devkota‡, Jaehoon Lee‡‡, Jae-il Roh‡, and Han-Woong Lee‡‡

From the ‡1Department of Biochemistry, College of Life Science and Biotechnology, and Laboratory Animal Research Center, Yonsei University, Seoul 120-749, Korea and the ‡‡Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon 440-746, Korea

The deficiency of retinoblastoma (Rb) gene deregulates E2F transcription factors and thus induces E2F target genes directly or p53 target genes indirectly via mouse p19A/M (or p14A/M in humans), an E2F target gene. Here, we identified that etoposide-induced 2.4 mRNA (Ei24)/p53-induced gene 8 (Pig8), a p53 target gene involved in apoptosis and autophagy, was up-regulated in Rb−/− mouse embryonic fibroblasts (MEFs). The Ei24 promoter was activated by E2F1 via multiple E2F-responsive elements, independently of the previously reported p53-responsive element. Chromatin immunoprecipitation assays revealed that E2F1 directly acts on the mouse Ei24 promoter. We observed that Ei24 expression was suppressed in p53−/− MEFs upon UVC irradiation, which was exacerbated in p53−/− E2f1−/− MEFs, supporting the positive role of E2F1 on Ei24 transcription. Furthermore, Ei24 knockdown sensitized p53−/− MEFs against UVC irradiation. Together, our data indicate that Ei24 is a novel E2F target gene contributing to the survival of p53-deficient cells upon UVC irradiation and thus may have a potential significance as a therapeutic target for treating p53-deficient tumors.

The retinoblastoma gene (Rb) was the first tumor suppressor gene to be identified in humans, and its loss of function is implicated in a wide variety of human cancers, including retinoblastomas (1). The Rb gene product (pRb) is a critical component of the cell cycle because it regulates the activity of E2F transcription factors, which induce the expression of genes required for cell cycle progression, including cyclins, cyclin-dependent kinases (CDKs), and proliferating cell nuclear antigen (2). When E2F is activated or deregulated, Rb-induced cell cycle arrest is compromised (3). Furthermore, deregulated E2F transcription factors can enforce quiescent cells to re-enter the cell cycle (4).

Growth arrest mediated by pRb/E2F is controlled by p53, which is a critical tumor suppressor known as the guardian of the genome (5). More than 50% of human cancers contain a mutation of p53 (6), and p53-mediated tumor suppression is mainly dependent on its activity as a transcription factor. The mutations occur most frequently in the DNA-binding domain of the p53 protein (7). In fact, p53 can activate a plethora of genes that regulate cell cycle progress, apoptosis, and DNA repair under stressful conditions (8). p21Waf1/Cip1 is a well known p53 target gene that is involved in the regulation of the Rb/E2F pathway. p21Waf1 can directly bind to and inhibit all cyclin-CDK complexes, whereas p16Ink4a specifically inhibits cyclin D-associated complexes of CDK4 and CDK6 (9). The resulting hypophosphorylation of pRb blocks the activation of E2F transcription factors.

In addition to their roles in cell cycle progression, E2F genes are important for apoptosis. In fact, diverse proapoptotic genes are directly regulated by E2F transcription factors (2), whose physiological significance has been demonstrated using mouse models deficient for E2F transcription factors. E2F1-deficient mice exhibit defects in apoptosis and are rather prone to tumorigenesis (10, 11). E2F2 and E2F3 are required for S phase entry induced by c-Myc (12). These phenotypes are supported by E2F-mediated regulation of proapoptotic genes including Bax/Bad, Apaf1, caspase-3, and caspase-9 (2).

Etoposide-induced 2.4 mRNA (Ei24), also known as p53-induced gene 8 (Pig8), was first identified as an up-regulated transcript in etoposide-treated NIH3T3 cells (13) and was later characterized as a p53 target gene (14). Ei24 was also identified as a prerequisite gene for executing autophagy (15). Because its ectopic expression induces cell death and suppresses cellular growth, Ei24 has been regarded as a tumor suppressor gene with a proapoptotic function (14). In support of this characterization, Ei24 is located on chromosome 11q24, which is fre-

---

*‡1 This work was supported by National Research Foundation of Korea Grants 2009-0081177 and 2010-0020878 funded by the Ministry of Education, Science, and Technology (MEST) of the Korean government and Korea Healthcare Technology R&D Project A085136 from the Ministry for Health and Welfare Affairs.

1 Both authors contributed equally to this work.

2 To whom correspondence may be addressed. Tel.: 82-2-2123-7642; Fax: 82-2-2123-8107; E-mail: sungyh@yonsei.ac.kr.

3 To whom correspondence may be addressed. Tel.: 82-2-2123-5698; Fax: 82-2-2123-8107; E-mail: hwil@yonsei.ac.kr.

4 The abbreviations used are: Rb, retinoblastoma; Apaf1, apoptosis protease-activating factor 1; CDK, cyclin-dependent kinase; CHX, cycloheximide; Ei24, etoposide-induced 2.4 mRNA; ER, estrogen receptor; MEF, mouse embryonic fibroblast; 4-OHT, 4-hydroxytamoxifen; Pig8, p53-induced gene 8; pRb, retinoblastoma gene product; RE, responsive element.
**Ei24 as an E2F Target Gene**

Quently lost in neoplastic lesions, including breast cancers (16). Furthermore, because Ei24 is a Bcl2-binding protein localized on the endoplasmic reticulum with potential roles in preventing the spreading of tumors (17), it is believed to be a critical downstream regulator of p53 in tumor suppression. We recently reported that Ei24 stabilizes protein kinase Ca (PKCa) and that its deficiency attenuates PKCa signaling and skin carcinogenesis in mice (18), suggesting that the physiological role of Ei24 is complex and may manifest differently according to tissue- and/or in a stress-specific manner.

Even though a large number of genes have been identified as E2F target genes, the role of pRb/E2F has not been fully elucidated. Recently, we analyzed the alteration in the gene expression pattern induced by Rb deficiency (19). Among the deregulated genes, the induction of Ei24 was observed in Rb−/− mouse embryonic fibroblasts (MEFs). In the present study, we characterized Ei24 as an E2F target gene, suggesting that Ei24 may act as a key mediator in the downstream pathways of both pRb/E2F and p53.

**EXPERIMENTAL PROCEDURES**

**Cell Culture, Transfection, and Reporter Gene Assay**—MEFs deficient for Rb, p53, and/or E2F1 were prepared as described previously (20). In addition to MEFs, NIH3T3 fibroblasts and H1299 cells were grown in DMEM containing 10% fetal bovine serum (Sigma). Reporter gene assays were conducted using the Dual-Luciferase Reporter Assay System (Promega). The mouse pRL-SV40 (Promega) was used as an internal control for the luciferase activity. Firefly and Renilla luciferase activities were measured 24 h after transfection using Dual-Luciferase Reporter Assay System (Promega) and a luminometer (Turner Designs).

**Constructs**—pBabe-HA-ER and pBabe-HA-ER-E2F1 were generous gifts from Dr. Kristian Helin (Biotech Research and Innovation Center, University of Copenhagen). pSG5L-HA-E2F1 (Addgene plasmid 10736) was routinely used as an effector for the luciferase and chromatin immunoprecipitation (ChIP) assays. pcDNA3-HA-E2F1, -E2F2, and -E2F3 were generous gifts from Dr. Joseph R. Nevins (Duke University) and were used to evaluate the effect of individual E2F members on the activation of the Ei24 promoter. pcDNA3-FLAG-p53 was a generous gift from Dr. Jaewhan Song (Yonsei University) and was used to validate the activation of the human Ei24 promoter.

**Stable Cell Lines and Treatments**—Retroviruses were generated with pBabe-HA-ER and pBabe-HA-ER-E2F1, as described previously, and were used for the infection (21). After selection with puromycin (Sigma), infected NIH3T3 cells were cloned and used after the expressions of HA-ER and HA-ER-E2F1 were confirmed. Cells were pretreated with cycloheximide (10 μg/ml, Sigma) for 1 h and then co-treated with 30 nm, 300 nm, or 3 μm 4-hydroxytamoxifen (4-OHT, Sigma) dissolved in ethanol for 24 h. Infectious lentiviral particles were produced as described previously (18) and were used to infect p53−/− MEFS. Infected cells were selected by treatment with puromycin (Sigma), and polyclonal cell populations were used for the following experiments. UVC irradiation and the following cell death assays, done by measuring fluorescein isothiocyanate (FITC)-labeled annexin V (annexin V-FITC) staining and propidium iodide permeability were conducted as described previously (20).

**Northern Blot Analysis and Semiquantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)**—Total RNAs were separated and transferred onto a nylon membrane (Amersham Bioscience). Prehybridization and hybridization were carried out as described previously (19). cDNA was synthesized using SuperScript III System (Invitrogen). RT-PCR analyses were conducted using the following primer pairs: 5′-CTTTTCTGAGGACCTTGCA-3′ and 5′-CTCTTGC-TGCCGCTCTACCTCTG-3′ for Ei24 (NM_007915). 5′-GGTGAAGAATGGAGAGCG-3′ and 5′-GTGCTATT-CCTCTCTCGC-3′ for Stackmin (NM_019641) (22), and 5′-ATCCTGCCACCCGAAAGAC-3′ and 5′-CACCACCT-TCTTGTGTACTC-3′ for Gapdh (NM_008084).

**ChIP Assays**—ChIP assays were done using the E2F1-specific antibody (sc-251x) and following the protocol from Santa Cruz Biotechnology. PCR amplification was performed using the following primers: 5′-CTAGCAAAATTAGCTGGTCCC-3′ (a forward primer specific for pGL3 Basic). 5′-AGTTCAGGC-AACTACAATT-3′ (−401/−382 of Ei24 promoter, used for detecting endogenous Ei24 promoter), and 5′-CCAGGCTGCTG-ATTGGCA-3′ (−88/−105, used for detecting endogenous Ei24 promoter and the Ei24 reporter gene construct).

**RESULTS**

Up-regulation of Ei24 in Rb−/− MEFS—To identify novel Rb/E2F-regulated genes, we previously analyzed the gene expression profile of Rb−/− MEFS (19). Among the deregulated genes, we observed the highly up-regulated expression of Ei24, which has been identified as a p53 target gene (14). Northern blot and quantitative RT-PCR analyses confirmed the significant increase of Ei24 mRNA in Rb−/− MEFS (Fig. 1, A and B). Consistent with this finding, known E2F target genes including apoptosis protease-activating factor 1 (Apaf1) (23) and Stackmin (22) were also up-regulated in Rb−/− MEFS (Fig. 1B). These data indicate that Ei24 expression can be regulated by Rb/E2F.

Because deregulated E2F1 directly up-regulates p19ARF, Rb deficiency alters the expressions of diverse p53 target genes (24). To examine whether Ei24 transcription is directly induced by E2F1, stable cell lines expressing the hemagglutinin (HA)-tagged ligand-binding domain of the estrogen receptor (ER) and estrogen receptor–fused E2F1 (ER-E2F1) were established.
using Ink4a/Arf-deficient NIH3T3 as a parental cell line (Fig. 1C). Because 4-OHT binding causes the translocation of the ER into the nucleus, the activity of ER-E2F1 can be conditionally activated by 4-OHT (25). These cell lines were pretreated with cycloheximide (CHX) to prevent de novo protein synthesis and then co-treated with 4-OHT for 24 h to activate the transcriptional activity of ER-E2F1 (Fig. 1, D and E). The data revealed that the Ei24 transcript level was considerably up-regulated in cells expressing ER-E2F1 but not in cells expressing ER only (Fig. 1D). Consistently, Stat3min, a known E2F target gene, showed a comparable expression pattern (Fig. 1D). In Fig. 1E, the effect of CHX treatment was confirmed by PKCα protein levels as a control on Western blot assays (18). Because de novo protein synthesis was blocked, these results indicate that Ei24 should be transcriptionally regulated by E2F1.

**Ei24 Is a Novel E2F Target Gene**—To identify potential cis-elements responsive to E2F transcription factors, the proximal region of the Ei24 promoter was analyzed with the TFBIND software (26). Three putative E2F-responsive elements (RE1, 2, and 3) and two cryptic REs with moderate similarity to the consensus were identified in the proximal region of mouse and human Ei24 promoters (Fig. 3A and data not shown). Based on this analysis, the corresponding regions of the Ei24 promoters were cloned from human and mouse genomes, and a series of reporter genes was constructed. Similar to mouse Ei24 (14), human Ei24 promoter was strongly activated by p53 (Fig. 2A). Because Rb deficiency up-regulated Ei24 expression in MEFs (Fig. 1A), and as pRb mainly regulates E2F1–3 (2), we examined the effect of these E2F transcription factors on the activation of the Ei24 promoter. Although E2F1–3 comparably activated the synthetic E2F-responsive reporter construct, they had variable effects on the activation of the Ei24 promoter (Figs. 2B and 3B). E2F1 showed an ~4-fold higher luciferase activity compared with basal activity, whereas E2F2 and E2F3 increased the activity by ~2-fold (Figs. 2B and 3B). These results suggest that, among the different E2Fs, deregulation of E2F1 has a major effect on the transcriptional activation of Ei24 in Rb−/− MEFs.

To discriminate the relative potential of the putative E2F-responsive elements on the Ei24 promoter, they were deleted or mutated. The longest promoter (~396 + 453) was strongly activated by E2F1 in NIH3T3 cells (Fig. 3C). The deletion of two cryptic REs had no effect on the E2F1-mediated activation of reporter genes, but the responsiveness of the Ei24 promoter—luciferase reporter to E2F1 was almost completely blocked by deleting RE1, 2, and 3 (Fig. 3C). In addition to the deletion, site-directed mutations in RE1 and RE2 significantly decreased E2F1-induced reporter gene activity but did not completely abolish the reporter gene activation by E2F1 (Fig. 3D, upper panel). An RE3 mutation had minimal effect when RE1 and 2 were intact (Fig. 3D, lower panel). However, the combined mutations of RE1–3 effectively suppressed the reporter gene activation by E2F1 (Fig. 3D, lower panel). These results imply that RE1, 2, and 3 are important for E2F-mediated activation of the Ei24 promoter.

Based on the E2F1-dependent activation of the Ei24 promoter, we examined whether E2F1 binds directly to the Ei24 promoter. An Ei24 reporter gene containing wild-type E2F-responsive elements was transiently transfected into H1299 cells with or without an E2F1 expression construct, and ChIP assays were conducted with an E2F1-specific antibody (Fig. 3E, left panel). Although the signals from the input were similar, a more prominent signal was detected in the cells transfected with the E2F1-expressing construct (Fig. 3E, left panel). As
E2F1 is functional in H1299 cells (27), a relatively weak signal may also be detected without E2F1 overexpression (Fig. 3E, left panel). To verify this result, the ChIP assay was done in an endogenous condition using wild-type and E2f1−/− MEFs with the same E2F1-specific antibody. The promoter region of the E2f1 promoter containing RE1–3 was specifically immunoprecipitated from the wild-type MEFs, but no signal was detected on all three REs, respectively. Consistent with these results, an up-regulated gene in p53−/− MEFSs (Fig. 4). Consistently, Statmin, an E2F target gene, showed a similar pattern of a reduction in expression in a time-dependent experiment (Fig. 4B). These results indicate that UVC irradiation suppresses E2f1 expression upon p53 deficiency and that E2F1 mitigates the negative effect of UVC irradiation on E2f1 expression in MEFs.

Because UVC irradiation is a potent inducer of both p53-dependent and p53-independent cell death, we examined whether E2f1 knockdown might affect UVC-induced cell death in p53−/− MEFSs. E2f1 expression was suppressed with lentiviruses encoding E2f1-specific short hairpin RNAs (shRNAs) in p53−/− MEFSs (Fig. 5A). When these MEFs were irradiated with 20 J/m² UVC, annexin V-FITC- and/or propidium iodide-stained cells were prominently detected at 24 and 48 h (Fig. 5B). Notably, E2f1 knockdown significantly increased UVC-induced cell death (Fig. 5, B and C). In contrast to previous reports showing the proapoptotic function of E2f1, these results provide evidence that E2f1 may have a protective role against UVC-induced cell death in p53-deficient genetic background.

DISCUSSION

In the present study, we identified E2f1, a p53 target gene, as an up-regulated gene in RB−/− MEFSs, and we subsequently characterized it as an E2F1 target gene. p53 and pRb/E2F are
closely related in modulating diverse cellular physiologies. When Rb is deficient, deregulated E2F up-regulates the expression of p19Arf, an important tumor suppressor gene alternatively encoded by Ink4a/Arf locus (24, 29, 30). p19Arf then executes a critical role in regulating the p53 activity by compromising the MDM2-mediated degradation of p53 (31–33). This molecular interaction allows diverse p53 and E2F target genes to be simultaneously induced in Rb−/− MEFs. Besides the Ink4a/Arf locus, cross-talk between p53 and pRb/E2F is also achieved by sharing target genes or by regulating distinct genes of a common physiological process. For example, Apaf1 is directly up-regulated by both p53 and E2F1 (23). Bax, a p53 target gene, and Apaf1, a common target of E2F and p53, are critical components for transducing intrinsic apoptotic signals and cooperate with E2F target genes including caspases-3 and 7–9, to properly execute apoptosis (34). Along these lines, considering its expressional regulation, EI24 may participate in cellular processes that are commonly governed by both p53 and E2F.

The potential significance of EI24 has been highlighted as a p53 target gene for apoptosis and growth suppression (14) and as an autophagy gene (15). As a lethal stress, UVC irradiation actively induces cell death through both p53-dependent and independent pathways (35, 36). Our results indicate that EI24 expression is suppressed by UVC irradiation (Fig. 3), presumably by the activation of pRb and/or its homologues, p107 and p130 (37). However, because this phenomenon was accelerated by E2f1 deficiency, E2F1 should have a positive role in regulating EI24 expression upon UVC irradiation. Previous studies have described EI24 as a proapoptotic gene, and thus its putative role as a tumor suppressor is expected (14, 17). In fact, etoposide induces EI24 expression (13), and EI24 knockdown confers cellular resistance to etoposide-induced cell death in NIH3T3 cells (38). Although these lines of evidence suggest the possible role of EI24 as a tumor suppressor, we recently reported that EI24-heterozygous knock-out mice manifested attenuated skin tumorigenesis phenotypes upon 7,12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) treatment (18). Consistently, EI24 knockdown sensitizes p53−/− MEFS to UVC irradiation (Fig. 5), raising the possibility that EI24 might exert a protective effect under a certain stress independently of p53. These results also suggest that the physiological role of EI24 in cell death is complicated and may be context- and/or environment-dependent. Meanwhile, its physiological role can be deduced from the function of EI24 as an autophagy gene (15).
**Ei24 as an E2F Target Gene**

Autophagy is also regulated by both p53 and p21Cip1 (39). Because UVC irradiation seriously damages cells, the damaged organelles, including mitochondria, should be removed by autophagy. If they are not properly eliminated by autophagy, lethal materials produced and released by the damaged mitochondria (e.g., reactive oxygen species or proapoptotic molecules) may make Ei24-silenced cells susceptible to UVC irradiation.

As Ei24 knockdown increased the sensitivity of p53−/− MEFs against UVC irradiation (Fig. 5), Ei24 might be critical for determining cellular survival under a certain stress independently of p53. In other words, it is highly possible that Ei24 is a critical factor modulating the survival of p53-deficient cells in human diseases, e.g., cancers. Therefore, Ei24 can be considered as a potential therapeutic target in p53-deficient tumors.

Taken together, these results imply that Ei24 is a critical mediator/effector required for the crosstalk between p53 and pRb/E2F pathways dedicated to tumor suppression. Therefore, understanding and identifying the specific conditions that require Ei24 may provide important clues for the prevention and treatment of neoplastic diseases in humans, and it may be helpful to scrutinize the molecular mechanisms of Ei24 action and to evaluate the extent of mutations and expression of Ei24 gene in diverse human cancers for proper cancer treatments.

Acknowledgments—We thank Dr. Joseph R. Nevins (Duke University), Dr. Kristian Helin (Biotech Research and Innovation Center, University of Copenhagen), and Dr. Jaewhan Song (Yonsei University) for their generous gifts described under “Experimental Procedures.”

**REFERENCES**

1. Goodrich, D. W., and Lee, W. H. (1993) Molecular characterization of the retinoblastoma susceptibility gene. *Biochim. Biophys. Acta* **1155**, 43–61.

2. Iaquinta, P. J., and Lees, J. A. (2007) Life and death decisions by the E2F transcription factors. *Curr. Opin. Cell Biol.* **19**, 649–657.

3. Qin, X. Q., Livingston, D. M., Ewen, M., Sellers, W. R., Arany, Z., and Kaelin, W. G., Jr. (1995) The transcription factor E2F-1 is a downstream target for RB action. *Mol. Cell. Biol.* **15**, 742–755.

4. Johnson, D. G., Schwarz, J. K., Cress, W. D., and Nevins, J. R. (1993) Expression of transcription factor E2F1 induces quiescent cells to enter S phase. *Nature* **365**, 349–352.

5. Polager, S., and Ginsberg, D. (2009) p53 and E2F: partners in life and death. *Nat. Rev. Cancer* **9**, 738–748.

6. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991) p53 mutations in human cancers. *Science* **253**, 49–53.

7. Harris, C. C. (1993) p53 at the crossroads of molecular carcinogenesis and risk assessment. *Science* **262**, 1980–1981.

8. Vogelstein, B., Lane, D., and Levine, A. J. (2000) Surfing the p53 network. *Nature* **408**, 307–310.

9. Zetterberg, A., Larsson, O., and Wiman, K. G. (1995) What is the restriction point? *Curr. Opin. Cell Biol.* **7**, 835–842.

10. Yamashita, J., Sato, H., Kato, T., Eto, H., and Miyazaki, K. (1996) Tumor induction and tissue atrophy in mice lacking E2F-1. *Cell* **85**, 537–548.

11. Field, S. J., Tsai, F. Y., Kuo, F., Zubiaga, A. M., Kaelin, W. G., Jr., Livingston, D. M., Orkin, S. H., and Greenberg, M. E. (1996) E2F-1 functions in mice to promote apoptosis and suppress proliferation. *Cell* **85**, 549–561.

12. Dever, D. M., Brehm, A., Bolognesi, P., Liu, J., and Zambetti, G. P. (1996) Identification and cloning of Ei24, a gene induced by p53 in etoposide-treated cells. *Oncogene* **12**, 1181–1187.

13. Gu, Z., Flemington, C., Chittenden, T., and Zambetti, G. P. (2000) Ei24, a p53 response gene involved in growth suppression and apoptosis. *Mol. Cell. Biol.* **20**, 233–241.

14. Tian, Y., Li, Z., Hu, W., Ren, H., Tian, E., Zhao, Y., Lu, Q., Huang, X., Yang, P., Li, X., Wang, X., Kovács, A. L., Yu, L., and Zhang, H. (2010) *C. elegans* screen identifies autophagy genes specific to multicellular organisms. *Cell* **141**, 1042–1055.

15. Gentile, M., Ahrnström, M., Schon, F., and Wingren, S. (2001) Candidate tumor suppressor genes at 11q23-q24 in breast cancer: evidence of alterations in *PIG8*, a gene involved in p53-induced apoptosis. *Oncogene* **20**, 7753–7760.

16. Zhao, X., Ayer, R. E., Davis, S. L., Ames, S. J., Florence, B., Torchinsky, C., Liou, J. S., Shen, L., and Spanjaard, R. A. (2005) Apoptosis factor Ei24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness. *Cancer Res.* **65**, 2125–2129.

17. Devkota, S., Sung, Y. H., Choi, J. M., Lee, J. H., Li, N. Y., Kim, H., Cho, B. C., Song, J., and Lee, H. W. (2012) Ei24-deficiency attenuates protein kinase Ca signal and skin carcinogenesis in mice. *Int. J. Biochem. Cell. Biol.* **44**, 1887–1896.

18. Sung, Y. H., Kim, J. H., and Lee, H. W. (2007) Identification of a novel Rb-regulated gene associated with the cell cycle. *Mol. Cells* **24**, 409–415.

19. Sung, Y. H., Kim, H. J., Devkota, S., Roh, J., Lee, J., Rhee, K., Bahn, Y. Y., and Lee, H. W. (2010) *Pierce 1*, a novel p53 target gene contributing to the ultraviolet-induced DNA damage response. *Cancer Res.* **70**, 10454–10463.

20. Naviaux, R. K., Costanzi, E., Haas, M., and Verma, I. M. (1996) The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. *J. Virology* **70**, 5701–5705.

21. Polager, S., and Ginsberg, D. (2003) E2F mediates sustained G1 arrest and down-regulation of Stathmin and AIM-1 expression in response to genotoxic stress. *J. Biol. Chem.* **278**, 1443–1449.

22. Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., and Vousden, K. H. (1998) *p14ARF* links the tumour suppressors RB and p53. *Nature* **395**, 124–125.

23. Vigo, E., Müller, H., Prosperini, E., Henzler, M., Martel, W., and Moroni, M. C., and Helin, K. (1999) *CDCA25A* phosphatase is a target of E2F and is required for efficient E2F-induced S phase. *Mol. Cell. Biol.* **19**, 6379–6395.

24. Heinemeyer, T., Chen, X., Kasas, H., Kel, A. E., Kel, O. V., Liebich, I., Meinhardt, T., Reuter, L., Schacherer, F., and Wingender, E. (1999) Expanding the TRANSFAC database towards an expert system of regulatory molecular mechanisms. *Nucleic Acids Res.* **27**, 318–322.

25. Wang, C., Chen, L., Hou, X., Li, Z., Kabra, N., Ma, Y., Nemoto, S., Finkel, T., Wu, G., Cress, W. D., and Chen, J. (2006) Interactions between E2F1 and Sirt1 regulate apoptotic response to DNA damage. *Nat. Cell Biol.* **8**, 1025–1031.

26. Lin, W. C., Lin, F. T., and Nevins, J. R. (2001) Selective induction of E2F response to DNA damage, mediated by ATM-dependent phosphorylation. *Genes Dev.* **15**, 1833–1844.

27. Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., and Roussel, M. F. (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. *Genes Dev.* **12**, 2424–2433.

28. Quelle, D. E., Zindy, F., Ashmun, R. A., and Sherr, C. J. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. *Cell* **83**, 993–1000.

29. Weber, J. D., Taylor, I. J., Roussel, M. F., Sherr, C. J., and Bar-Sagi, D. (1999) Nucleolar Arf sequesters Mdm2 and activates p53. *Nat. Cell Biol.* **1**, 20–26.

30. Honda, R., and Yasuda, H. (1999) Association of *p19ARF* with Mdm2 in cells lacking p53. *Nat. Cell Biol.* **2**, 233–239.

31. Sherr, C. J. (2001) The INK4a/ARF network in tumor suppression. *Nat. Rev. Mol. Cell Biol.* **2**, 731–737.
Ei24 as an E2F Target Gene

34. Nahle, Z., Polakoff, J., Davuluri, R. V., McCurrach, M. E., Jacobson, M. D., Narita, M., Zhang, M. Q., Lazebnik, Y., Bar-Sagi, D., and Lowe, S. W. (2002) Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol. 4, 859–864.

35. Latonen, L., Taya, Y., and Laiho, M. (2001) UV-radiation induces dose-dependent regulation of p53 response and modulates p53-HDM2 interaction in human fibroblasts. Oncogene 20, 6784–6793.

36. Mailand, N., Falck, J., Lukas, C., Syljuåsen, R. G., Welcker, M., Bartek, J., and Lukas, J. (2000) Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425–1429.

37. Black, A. R., and Azizkhan-Clifford, J. (1999) Regulation of E2F: a family of transcription factors involved in proliferation control. Gene 237, 281–302.

38. Mork, C. N., Faller, D. V., and Spanjaard, R. A. (2007) Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. FEBS Lett. 581, 5440–5444.

39. Polager, S., Ofir, M., and Ginsberg, D. (2008) E2F1 regulates autophagy and the transcription of autophagy genes. Oncogene 27, 4860–4864.